bioMérieux - First-Half 2011 Business Review

Marcy L'Etoile, France - July 19, 2011. At constant exchange rates and comparable business base*

• First-half sales up 4.3%
• Second-quarter sales accelerate: up 5.1%
  
  • Good performance in North America confirmed: up 5.1%
  • Strong increase in China: up 35%
• Two strategic acquisitions during the period
• Confirmation of the 2011 objective for sales growth
• Jean-Luc Bélingard, Chairman of the Board, takes on the role of CEO, heading the Management Committee, and Stéphane Bancel joins Institut Mérieux as Senior Advisor

* Excluding the impact of discontinuing culture media for the routine clinical test business in North America

bioMérieux, a world leader in the field of in vitro diagnostics, today released its business review for the six months ended June 30, 2011.
Net sales for the first half of 2011 amounted to €673 million, a 4.3% year-on-year increase, at constant exchange rates and comparable business base (excluding the impact of discontinuing culture media for the routine clinical test business in North America). The increase was led by dynamic sales in North America, Latin America and Asia-Pacific.
Sales growth accelerated in the second quarter to 5.1% at constant exchange rates and comparable business base, led in particular by strong growth in China.